Biogen has downbeat news about its gene therapy for the rare inherited eye disease, X-linked retinitis pigmentosa, announcing the shot failed to meet its target in a phase 2/3 study. A final FDA ...
The Dis-Chem Half Marathon has relaunched to become the Biogen Half Marathon presented by Momentum Multiply for 2025. After 22 years, Dis-Chem announced that its leading sports and wellness brand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback